UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies

This first-in-human Phase 1/2 study tests UKK-0018, a new investigational injectable immunotherapy designed to gradually retrain the immune system to tolerate peanut proteins, reducing the risk of allergic reactions in people with peanut allergy. Unlike standard oral immunotherapy, UKK-0018 has been modified to reduce binding to IgE antibodies — the molecules responsible for triggering allergic reactions — which may make the treatment safer. Adults aged 18–55 with a physician-confirmed peanut allergy, a positive skin prick test, and a confirmed reaction to peanut protein during a supervised challenge test are eligible; those with uncontrolled asthma, cardiovascular disease, active infections, a history of life-threatening anaphylaxis, or who are pregnant are excluded. The study has a screening period, an injection period with escalating dose levels, and a follow-up period to assess immune changes and safety. This summary was prepared as patient-facing educational content using AI assistance.